NanOlogy
  • Home
  • About
  • Technology
    • Overview
    • Purcision Technology
  • Development
    • Investigational Drugs
    • Pipeline
    • Clinical Trials
    • Partnering Opportunities
  • News & Publications
  • Contact Us
    • Partnering Opportunities
    • Physicians and Patients
Post placeholder image
December 20, 2022 in NanOlogy Press Release

NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts

NanOlogy 0 Like Post Comments Off on NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts

NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts FORT WORTH (December 20, 2022) — NanOlogy LLC, a clinical-stage interventional oncology d ...

Read More
NanOlogy

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.    Purcision is a trademark to CritiTech, Inc.  © NanOlogy LLC      Legal